Skip Nav Destination
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Issue Archive
Table of Contents
Editorial
Inside Blood
Blood Work
Plenary Paper
Perspectives
Review Articles
Clinical Trials and Observations
Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease
Clinical Trials & Observations
Saro H. Armenian,Can-Lan Sun,Tabitha Vase,Kirsten K. Ness,Emily Blum,Liton Francisco,Kalyanasundaram Venkataraman,Raynald Samoa,F. Lennie Wong,Stephen J. Forman,Smita Bhatia
Gene Therapy
Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice
Brief Report
Alessio Cantore,Nisha Nair,Patrizia Della Valle,Mario Di Matteo,Janka Màtrai,Francesca Sanvito,Chiara Brombin,Clelia Di Serio,Armando D'Angelo,Marinee Chuah,Luigi Naldini,Thierry VandenDriessche
Immunobiology
HCV glycoprotein E2 is a novel BDCA-2 ligand and acts as an inhibitor of IFN production by plasmacytoid dendritic cells
Jonathan Florentin,Besma Aouar,Clélia Dental,Christine Thumann,Guylène Firaguay,Francoise Gondois-Rey,Vassili Soumelis,Thomas F. Baumert,Jacques A. Nunès,Daniel Olive,Ivan Hirsch,Ruzena Stranska
CD8 T cells induce T-bet–dependent migration toward CXCR3 ligands by differentiated B cells produced during responses to alum-protein vaccines
Karine Serre,Adam F. Cunningham,Ruth E. Coughlan,Andreia C. Lino,Antal Rot,Elin Hub,Katrin Moser,Rudolf Manz,Alastair Ferraro,Roger Bird,Kai-Michael Toellner,Jocelyne Demengeot,Ian C. M. MacLennan,Elodie Mohr
Lymphoid Neoplasia
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone
Brief Report
David I. Lichter,Hadi Danaee,Michael D. Pickard,Olga Tayber,Michael Sintchak,Hongliang Shi,Paul G. Richardson,Jamie Cavenagh,Joan Bladé,Thierry Façon,Ruben Niesvizky,Melissa Alsina,William Dalton,Pieter Sonneveld,Sagar Lonial,Helgi van de Velde,Deborah Ricci,Dixie-Lee Esseltine,William L. Trepicchio,George Mulligan,Kenneth C. Anderson
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia
Rosa Lapalombella,Qingxiang Sun,Katie Williams,Larissa Tangeman,Shruti Jha,Yiming Zhong,Virginia Goettl,Emilia Mahoney,Caroline Berglund,Sneha Gupta,Alicia Farmer,Rajeswaran Mani,Amy J. Johnson,David Lucas,Xiaokui Mo,Dirk Daelemans,Vincent Sandanayaka,Sharon Shechter,Dilara McCauley,Sharon Shacham,Michael Kauffman,Yuh Min Chook,John C. Byrd
PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium
Brief Report
Alexandra Nieters,Lucia Conde,Susan L. Slager,Angela Brooks-Wilson,Lindsay Morton,Danica R. Skibola,Anne J. Novak,Jacques Riby,Stephen M. Ansell,Eran Halperin,Tait D. Shanafelt,Luz Agana,Alice H. Wang,Anneclaire J. De Roos,Richard K. Severson,Wendy Cozen,John Spinelli,Katja Butterbach,Nikolaus Becker,Silvia de Sanjose,Yolanda Benavente,Pierluigi Cocco,Anthony Staines,Marc Maynadié,Lenka Foretova,Paolo Boffetta,Paul Brennan,Qing Lan,Yawei Zhang,Tongzhang Zheng,Mark Purdue,Bruce Armstrong,Anne Kricker,Claire M. Vajdic,Andrew Grulich,Martyn T. Smith,Paige M. Bracci,Stephen J. Chanock,Patricia Hartge,James R. Cerhan,Sophia S. Wang,Nathaniel Rothman,Christine F. Skibola
Myeloid Neoplasia
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response
Brief Report
Amir T. Fathi,Hossein Sadrzadeh,Darrell R. Borger,Karen K. Ballen,Philip C. Amrein,Eyal C. Attar,Julia Foster,Meghan Burke,Hector U. Lopez,Christina R. Matulis,Katherine M. Edmonds,A. John Iafrate,Kimberly S. Straley,Katharine E. Yen,Samuel Agresta,David P. Schenkein,Cedric Hill,Ashkan Emadi,Donna S. Neuberg,Richard M. Stone,Yi-Bin Chen
Phagocytes, Granulocytes, and Myelopoiesis
-
Cover Image
Cover Image
![issue cover]()
Top: Wright-Giemsa stained cytospins of mouse bone marrow cells transformed with MLL-AF9. In these cells, MLL-AF9 is bound to menin via its N-terminal MLL fragment. The crystal structure in the inset shows the menin with bound fragment of MLL (purple). Bottom: Differentiation of the mouse bone marrow cells transformed with MLL-AF9 upon treatment with menin inhibitor MI-2-2. The inset shows the crystal structure of menin with bound MI-2-2 inhibitor (red), which displaces MLL-AF9 from menin and relieves the differentiation block caused by MLL-AF9. See the article by Shi et al on page 4461.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
